- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03733431
Non-invasive TRanscutaneous Cervical Vagus Nerve Stimulation as a Treatment for Acute Stroke; Safety and Feasibility Study (TR-VENUS)
October 4, 2021 updated by: Ethem Murat Arsava, Turkish Stroke Research and Clinical Trials Network
This study aims to determine safety and feasibility of non-invasive transcutaneous cervical Vagus nerve stimulation (nVNS) when delivered promptly after clinical diagnosis of acute stroke.
Vagus nerve stimulation will be performed via GammaCore® device.
A total of 60 patients will be randomized to each of 3 different groups; 'standard dose' vagal stimulation, 'high dose' vagal stimulation, and 'sham stimulation' (1:1:1 ratio).
Adverse device events, serious adverse device events, and feasibility of vagal nerve stimulation at the setting of acute stroke will be evaluated.
The study will be performed in a multi-center fashion among stroke centers within TurkStrokeNet Network.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
69
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Ankara, Turkey
- Ankara University Faculty of Medicine
-
Ankara, Turkey
- Gazi University Faculty of Medicine
-
Ankara, Turkey
- Hacettepe University Faculty of Medicine
-
Antalya, Turkey
- Akdeniz University
-
Eskişehir, Turkey
- Eskişehir Osmangazi Faculty of Medicine
-
Konya, Turkey
- Necmettin Erbakan University
-
Konya, Turkey
- Selcuk University
-
Samsun, Turkey
- Ondokuz Mayıs University Faculty of Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female patients who are older than 18 years old who have been admitted to neurological intensive care or stroke units with ischemic or hemorrhagic stroke
- Patients with symptom onset time within 6 hours or with unknown time of onset and no evidence of acute ischemia on fluid attenuation inversion recovery (FLAIR) imaging
- Patients who have given written informed consent prior to undertaking any study-related procedure.
Exclusion Criteria:
- Patients who have a pre-stroke disability ≥ 2 according to the modified Rankin Score
- Patients who have a NIH Stroke Scale/Score (NIHSS) ≤ 4 or ≥30
- Patients who have a NIHSS item 1a ≥2
- Patients who have experienced early dramatic neurological improvement (NIHSS score improvement ≥8) prior to study randomization suggesting resolution of signs/symptoms of stroke
- Patients with classical lacunar syndrome
- Patients who have local infection, rash or space occupying lesion at the stimulation site
- Patients with a prior injury to the vagus nerve (cervical vagotomy)
- Patients with conditions that make the positioning of the device not possible such as tonic head deviation or involuntary movements of the head and neck
- Patients using medications that can interfere with central neurotransmitter mechanisms potentially involved in the central vagal pathway (complete list is provided below under concomitant medications)
- Patients with known severe (>90% stenosis) bilateral carotid artery disease
- Patients with known carotid hypersensitivity
- Patients who had undergone bilateral carotid endarterectomy or neck surgery involving the region of carotid triangle
- Patients who have low blood pressure (Baseline SBP≤100 mmHg or DBP≤60 mmHg)
- Patients who have slow heart rate (Baseline HR≤60/min)
- Patients who have high blood pressure (SBP>220 mmHg or DBP>130 mmHg) despite initial line of treatment
- Patients who have been involved in any investigational study within the previous 90 days
- Patients who have any terminal illness such that the patient would not be expected to survive more than 90 days
- Pregnant women
- Patients with severe hypoglycemia at admission (<60 mg/dl)
- Patient experiencing seizures
- Patients with baseline ECG showing first-degree AV block; second- or third-degree atrio-ventricular block with no pacemaker/ICD in place; or ventricular tachycardia/fibrillation
- Patients with digitalis toxicity
- Patients who are suspected to have an acute coronary syndrome after clinical evaluations (Clinical, ECG, or any related biomarker)
- Patients who are scheduled to have an emergent carotid artery angioplasty stenting or endarterectomy
- Patients implanted with an electrical and/or neurostimulator device, including but not limited to cardiac pacemaker or defibrillator, vagal neurostimulator, deep brain stimulator, spinal stimulator, bone growth stimulator, or cochlear implant.
- Patients implanted with metal cervical spine hardware or having a metallic implant near the GammaCore stimulation site.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Standard dose vagal stimulation
A total of 7 consecutive 2-minute trains at every 10 minutes for one hour (n=20)
|
Transcutaneous stimulation of vagus nerve with the device positioned below the mandibular angle, medial to the sternocleidomastoid muscle and lateral to the larynx.
|
Active Comparator: High dose vagal stimulation
A total of 7 consecutive 2-minute trains applied at every 10 minutes for one hour that is followed by an additional 7 consecutive 2-minute trains interspersed at every 10 minutes applied 3 hours after completion of the initial scheme (n=20)
|
Transcutaneous stimulation of vagus nerve with the device positioned below the mandibular angle, medial to the sternocleidomastoid muscle and lateral to the larynx.
|
Sham Comparator: Sham stimulation
A total of 7 consecutive 2-minute trains at every 10 minutes for one hour (n=20)
|
Sham device which does not deliver electrical stimulation, but instead, produces a buzzing sound will be placed along the lateral border of the sternocleidomastoid muscle in order to avoid mechanical stimulation of the vagus nerve in the carotid triangle.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cardiovascular effects, clinical worsening or death (primary safety measure)
Time Frame: 24 hours
|
any of the following:
|
24 hours
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of treatment eligible patients (feasibility measure 1)
Time Frame: 6 hours
|
Proportion of eligible patients in whom nVNS can be started within the first 6 hours.
|
6 hours
|
Proportion of patients completing all pre-specified treatment doses (feasibility measure 2)
Time Frame: 12 hours
|
Proportion of enrolled patients who receive all the pre-specified treatment doses per protocol.
|
12 hours
|
Stroke onset to treatment time (feasibility measure 3)
Time Frame: 6 hours
|
Time from stroke onset to administration of the first dose of nVNS.
|
6 hours
|
Early neurological outcome (efficacy measure 1)
Time Frame: 24 hours
|
Proportion of patients with NIHSS score≤4 or improvement of baseline NIHSS score ≥8 at 24 hours
|
24 hours
|
Early tissue outcome (efficacy measure 2)
Time Frame: 24 hours
|
Delta infarct volume between baseline DWI and 24 hr MRI.
|
24 hours
|
Local reaction at application site (secondary safety measure 1)
Time Frame: 12 hours
|
Local irritation or skin reaction during treatment application
|
12 hours
|
Acute coronary syndrome (secondary safety measure 2)
Time Frame: 24 hours
|
Acute coronary syndrome
|
24 hours
|
Symptomatic intracerebral hemorrhage (secondary safety measure 3)
Time Frame: 24 hours
|
Symptomatic intracerebral hemorrhage: ≥ 4 points increase in NIH Stroke Scale Score (NIHSS) together with a PH2 (parenchymal hematoma-2) type intracerebral hemorrhage
|
24 hours
|
Death, clinical worsening, and acute coronary syndrome (secondary safety measure 4)
Time Frame: 24 hours
|
Combined outcome of death, clinical worsening, and acute coronary syndrome
|
24 hours
|
New ischemic lesion or increase in hemorrhage (secondary safety measure 5)
Time Frame: 24 hours
|
New, spatially distinct remote ischemic lesion outside the arterial territory of the index lesion on MRI at 24 hours or greater than 30% increase in hemorrhage volume from baseline CT to 24 hour MRI in the subset with intracerebral hemorrhage
|
24 hours
|
Serious adverse device event (SADE) rate (secondary safety measure 6)
Time Frame: 24 hours
|
Serious adverse device event (SADE) rate at 24 hours
|
24 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Ethem M Arsava, MD, Hacettepe University
- Principal Investigator: Mehmet A Topcuoglu, MD, Hacettepe University
- Study Chair: Hakan Ay, MD, Massachusetts General Hospital, Harvard University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 10, 2019
Primary Completion (Actual)
December 31, 2020
Study Completion (Actual)
April 1, 2021
Study Registration Dates
First Submitted
November 3, 2018
First Submitted That Met QC Criteria
November 6, 2018
First Posted (Actual)
November 7, 2018
Study Record Updates
Last Update Posted (Actual)
October 5, 2021
Last Update Submitted That Met QC Criteria
October 4, 2021
Last Verified
October 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TR-VENUS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stroke
-
University Hospital, GhentRecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Stroke HemorrhagicBelgium
-
Moleac Pte Ltd.RecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, CryptogenicSingapore, Philippines
-
Moleac Pte Ltd.Not yet recruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, Cryptogenic
-
IRCCS San Camillo, Venezia, ItalyRecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke HemorrhagicItaly
-
Vanderbilt University Medical CenterPatient-Centered Outcomes Research Institute; University of Alabama at BirminghamEnrolling by invitationStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Engagement, Patient | Stroke HemorrhagicUnited States
-
University of MinnesotaAmerican Occupational Therapy FoundationRecruitingStroke | Stroke Sequelae | Stroke Hemorrhagic | Stroke IschemicUnited States
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Michael Smith Foundation for...RecruitingStroke | Stroke, Ischemic | Stroke Hemorrhagic | Chronic StrokeCanada
-
University of CincinnatiMedical University of South Carolina; University of California, Los Angeles; University...RecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke HemorrhagicUnited States
-
University of LiegeCompletedStroke, Acute | Stroke Hemorrhagic | Stroke, ComplicationBelgium
-
University Hospital Inselspital, BerneUnknownEmergencies | Stroke, Acute | Stroke Hemorrhagic | Diagnostic Self Evaluation | Strokes Thrombotic | Stroke SyndromeSwitzerland
Clinical Trials on Gammacore device
-
CentraCareElectroCore INCCompletedTraumatic Brain Injury | Acute Brain InjuriesUnited States
-
ElectroCore INCCompleted
-
ElectroCore INCCompletedCluster HeadacheUnited States
-
University of Toledo Health Science CampusElectroCore INCTerminatedRaynaud Disease | Raynaud Phenomenon | Primary Raynaud Phenomenon | Raynaud SyndromeUnited States
-
Aalborg University HospitalElectroCore INCCompletedDiabetes Mellitus | Gastrointestinal DysfunctionDenmark
-
Rigshospitalet, DenmarkAalborg University HospitalNot yet recruitingFatigue | Systemic Lupus Erythematosus | Autonomic Dysfunction | Autonomic Neuropathy
-
Jens Brøndum FrøkjærElectroCore INCCompletedNeuropathic Pain | Visceral Pain | Painful Chronic PancreatitisDenmark
-
Emory UniversityGeorgia Institute of TechnologyCompletedPostTraumatic Stress DisorderUnited States
-
University of Texas Southwestern Medical CenterElectroCore INCWithdrawnPost-Traumatic HeadacheUnited States
-
ElectroCore INCCompletedMigraine DisordersUnited States